Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company's macular degeneration treatment. If you like this story, sign up for Jim Cramer's Top 10 Morning Thoughts on the Market email newsletter for free. CNBC's Jim Cramer said on "Squawk on the Street" that Regeneron is one of his favorite health-care names, describing Eylea as "a remarkable drug for macular degeneration." "I think being up [11 points] is not enough," Jim said as shares traded $11 higher. The CNBC Investing Club with Jim Cramer doesn't own Regeneron.

---

Persons: Jim Cramer's, CNBC's Jim Cramer, Leonard Schleifer's, Jim, Jim Cramer doesn't, Eli Lilly Organizations: Regeneron Pharmaceuticals, Food and Drug Administration, CNBC